Homocysteine, B-vitamins and CVD

Area of Science:

• Cardiovascular disease research
• Nutritional science
• Genetics and public health

Background:

• Plasma homocysteine (tHcy) is a recognized risk factor for cardiovascular disease (CVD).
• Previous trials on B-vitamin intervention for tHcy lowering have yielded inconclusive results regarding CVD event reduction.
• Genetic factors, like the MTHFR C677T variant, significantly influence tHcy levels and heart disease risk.

Purpose of the Study:

• To explore the role of folate and related B-vitamins in the primary prevention of CVD.
• To investigate the implications of B-vitamin interventions for nutrition policy.
• To examine the impact of genetic variations on tHcy levels and CVD risk.

Main Methods:

• Review of existing clinical trials and meta-analyses on tHcy and CVD.
• Analysis of genetic studies identifying MTHFR variants as determinants of tHcy.
• Assessment of the metabolic pathways involving B-vitamins (folate, B12, B6, riboflavin) in homocysteine regulation.

Main Results:

• Folic acid supplementation has been shown to reduce stroke risk, particularly in individuals without prior stroke history.
• Individuals with the MTHFR TT genotype exhibit a significantly higher risk of heart disease (14-21%).
• Plasma tHcy levels are responsive to B-vitamin interventions, with folic acid being particularly effective, and riboflavin showing specific benefits for the TT genotype.

Conclusions:

• Folic acid fortification, while primarily for neural-tube defect prevention, may play a crucial role in primary CVD prevention by lowering tHcy.
• B-vitamins, including folate and riboflavin, are essential for homocysteine metabolism and can modulate CVD risk, especially in genetically susceptible populations.
• Nutrition policies should consider the potential of B-vitamin fortification for public health initiatives targeting CVD prevention.